- Aesthetic Medicine
- Aesthetic Surgery
- ALS Treatment
- Brain Injury Treatment
- Cerebral Palsy
- Cerebral Palsy Treatment
- FDA Stem Cell Trials
- Gene Therapy Trials
- Hormone Replacement Therapy
- Mesenchymal Stem Cells
- MS Treatment
- Muscular Dystrophy Treatment
- Parkinson's Treatment
- Retinitis Pigmentosa
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Ulcerative Colitis
Category Archives: Stem Cell Clinical Trials
Posted: September 25, 2015 at 7:47 pm
To use this resource, simply select the condition you are interested in from the categories displayed in the menu. For example, if you are interested in trials for Macular Degeneration, then select ‘Vision loss’ and ‘Macular Degeneration’ from the drop down menu.If the condition you are interested in is not listed, please use the search function on the USNIH Clinical Trials website.
This website provides information about current or recently completed stem cell clinical trials but to find out more about each trial click on the ‘Link to Clinical Registry’ button. You can also click here to see a summary of the stem cell clinical trials in Australia.
It is important to remember that just because a treatment is being evaluated as part of a clinical trial, that does not make it a proven safe and effective therapy. These trials are experimental. Visit What are clinical trials? to learn more. Please use this listing for your research, but continue to speak to your treating Australiandoctors for independent advice on what is best for you.
Posted: April 21, 2015 at 12:40 am
China's Stem Cell Tech Development–CCTV News
China's stem cell research ranks the 3rd-highest number of ongoing stem cell clinical trials in the world.
By: Norgen Healthcare International
Posted: October 28, 2014 at 4:42 am
One of the more exciting aspects of FFBs recent annual conference, VISIONS 2013, was the news on the clinical development of several emerging stem cell therapies. The field has picked up a lot of steam, with many new human studies of stem-cell treatments anticipated to begin in 2014 and 2015.
Whats particularly noteworthy is that some of these trials will be for people with retinitis pigmentosa (RP) a population not yet included in human stem-cell studies. Also, investigators will evaluate new types of cells and new, innovative approaches to implanting them.
Heres a review of three of the stem-cell clinical studies on the horizon:
Riken Institute: Sheets of RPE Derived from Induced Pluripotent Stem Cells
In June, the Japanese Health Ministry gave approval to the Riken Institute to launch a clinical trial of sheets of retinal pigment epithelial (RPE) cells for the treatment of wet age-related macular degeneration (AMD). The study is planned for 2014.
The sheets will replace native RPE cells damaged by leaky blood vessels, which are the hallmark of wet AMD. RPE cells play a critical role in supporting photoreceptors, the cells that make vision possible.
For the first time in a human study, the researchers will produce RPE cells from induced pluripotent stem cells (iPSC) stem cells derived by turning back the development clock on a small sample of skin taken from the patient. The stem cells are then coaxed forward to become RPE. Because the cells come from the patient, theres less chance of immune rejection.
David Gamm, M.D., Ph.D., of the University of Wisconsin-Madison, said that transplanting sheets of RPE cells rather than injecting a bolus or a clump of cells was likely to produce better results, because RPE cells naturally occur as a layer in the retina. He believes that sheets of cells have a better chance to integrate and function normally.
By the way, Dr. Gamm, in collaboration with Dennis Clegg, Ph.D., of the University of California, Santa Barbara, is receiving Foundation funding to develop a patch of cells comprised of photoreceptors and RPE cells for treating retinal diseases. While his work is still a few years away from the clinic, it is very promising, because so many retinal diseases affect both of these cell types.
UC Irvine: Retinal Progenitor Therapy for Reactivating the Retina
See original here:
Several New Stem Cell Clinical Trials Poised to Begin in …
Posted: October 12, 2014 at 4:43 am
Spinal Cord Injury and Stem Cell Clinical Trials: Whats the Latest?
Join California's Stem Cell Agency (CIRM) for a live Google Hangout about the latest progress in stem cell-based treatments for spinal cord injury. You don't need a Google+ account to watch…
By: California Institute for Regenerative Medicine
Posted: July 1, 2014 at 8:42 am
The therapeutic potential of stem cells has so profoundly changed the landscape of medical research that it has spawned an entirely new field regenerative medicine.
There is indeed a great deal of promise, but also a tendency to think that a cure is just around the corner. The path from research to the clinic is often long and complicated, with many small advances. Our aim is to present an objective view of the most important advances, to provide a foundational knowledge against which to read and evaluate new research as it emerges.
A recent Canadian report examined the state of novel stem cell clinical trials around the world. Find out more here.
Generally, it is helpful to understand four different approaches to using stem cells for clinical benefit, in addition to their still critical role in understanding the disease process.
Stem cell transplantation Cellular therapy Tissue regeneration Drug discovery
General information on clinical trials Where can I find out about ongoing stem cell therapies or clinical trials?
Stem cell transplantation exploits the special characteristics of stem cells to multiply indefinitely and to become other cells required by the body. For example, stem cells that reside in the bone marrow or are plentiful in cord blood are removed and used to generate new blood cells. These are then transplanted back into the body, thereby restoring a patient’s immune system and capacity to fight disease.
Cellular therapy relies on stem cells’ ability to regenerate indefinitely and to evolve from one kind of cell to another based on elaborate codes and cues. Stem cells residing in our own tissues may be re-programmed, or new ones manufactured artificially through therapeutic cloning, to replace the cells damaged by disease or injury. Then, these can be generated in large enough quantities for transplantation.
While stem cells help scientists to understand the mechanisms and pathways that initiate and perpetuate disease, it is now evident that they can also be mobilized to reverse this process. By manipulating growth factors that enhance stem cell activity and silencing the genes that drive disease, scientists are already demonstrating that stem cells will be able to regenerate tissue and restore lost function.
Originally posted here:
Stem Cell Clinical Trials – Canadian Stem Cell Foundation
Posted: March 16, 2014 at 3:53 pm
Promising Research Promising research and progress underscores the need to increase funding for adult stem cell research. Here youll find the best of the best in current adult stem cell research. This section will keep you up to date on ongoing research and new findings.
If youre interested in participating in a clinical trial, please visit ClinicalTrials.gov and perform a search using the terms relevant to your situation. Additionally, you can check the List of Treatable Conditions link, scroll to the bottom of the section and click any links we have found to be helpful regarding this condition/disease. In some cases a link may already be available to perform an automatic search on ClinicalTrials.gov.
Unfortunately, at this time the National Stem Cell Foundation is only able to fund research. NSCF is unable to fund patient participation in a clinical trial on an individual basis.
A word about clinical trials:
Medical research studies involving people are called clinical trials. Clinical trials look at
Trials aim to find out if a new experimental drug or procedure
New treatments have to be thoroughly tested. A new drug, for example is investigated first in the laboratory. If it looks promising, it is carefully studied in people.
There are three different types of clinical trials. These are called phase 1, 2 and 3. Phase 1 is the earliest trials in the life of a new drug or treatment. They are usually small trials, recruiting anything up to 30 patients (often a lot less).
About 70 out of every 100 new treatments tested at phase 1 make it to phase 2 trials. Phase 2 trials are often larger than phase 1. There may be up to 50 people taking part. If the results of phase 2 trials show that a new treatment may be as good as existing treatment, or better, it then moves to phase 3.
Phase 3 trials compare new treatments with the best currently available treatment (the standard treatment). Phase 3 trials are usually much larger than phase 1 or 2. This is because differences in success rates may be small. So, you would need very many results to show the difference. Sometimes phase 3 trials involve thousands of patients in many different hospitals and even different countries. Phase 3 trials are usually randomized. This means the researchers put the people taking part into 2 groups at random. One group gets the new treatment and the other the standard treatment.
Posted: February 18, 2014 at 12:41 am
Matt Valente Interview w/ Dr. Wise Young @WMKECK Center Rutgers University
An excerpt from an interview I held with Dr. Wise Young of Rutgers Universities WMKECK Center. Stem Cell Clinical Trials Need to be conducted in the USA! The…
By: Matt Valente
Posted: January 16, 2014 at 6:45 pm
Stem cell science is commonly subject to widely varying treatment at the hands of the media and this is due, in part, to a poor understanding in general of the importance of clinical trials and proper research in the pursuit of knowledge prior to application of a new treatment modality. Clinics offering stem cell therapy often rely on the vulnerability of many patients and their poor understanding of science in order to bamboozle them with faux-science and convince them of the unproven merits of their expensive treatments.
Who amongst us is likely to confess ignorance when facing a seemingly qualified doctor in a hospital-like setting discussing matters often of life and death? To ask for clinical evidence and raw data of a treatments efficacy is unlikely to get you very far in most cases, and even if the data were provided would you be any better equipped to make an informed choice about medical treatment? What is a clinical trial, how do they help us in real life, and can they be dangerous?
Read on about: The Importance of Clinical Trials
See the original post:
Stem Cell Clinical Trials | Stem Cell Research
Posted: November 28, 2013 at 5:44 pm
Los Angeles – July 24, 2013 Timothy D. Henry, MD, an expert known for his innovative work in developing stem cell treatments for advanced heart disease patients, has joined the Cedars-Sinai Heart Institute as director of Cardiology.
Henry comes to Cedars-Sinai from Minneapolis, where he was director of research for the Minneapolis Heart Institute Foundation and professor of medicine at the University of Minnesota School of Medicine.
As Henry begins his tenure, Prediman K. Shah, MD, the renowned cardiologist who has led the Division of Cardiology for nearly 20 years, is stepping down to focus on patient care and on basic and clinical research, including his quest to develop a vaccine and mutant-gene-based therapies that would thwart heart attacks by preventing and possibly reversing arterial cholesterol buildup. Shah, the Shapell and Webb Family Chair in Clinical Cardiology, director of the Oppenheimer Atherosclerosis Research Center and director of the Atherosclerosis Prevention and Treatment Center, also will continue treating patients and teaching medical residents and cardiology trainees.
Dr. Shah has been a wonderful colleague and a highly respected national leader, accelerating the pre-eminence of our Cardiology Division, and Dr. Henry will be starting his new position from a robust platform built over many decades of outstanding service, said Shlomo Melmed, MD, senior vice president of Academic Affairs, dean of the Cedars-Sinai medical faculty and the Helene A. and Philip E. Hixon Chair in Investigative Medicine. We are delighted that Dr. Shah will be remaining on as a senior cardiologist in our Heart Institute.
This is a milestone moment, said Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute. At the same time we celebrate Dr. Shahs achievements and his valuable contributions to the Heart Institute and to overall heart health, we are welcoming Dr. Henry and beginning a new era during which we foresee the next wave of leading-edge stem cell clinical trials for heart disease patients.
For several years, Henry has been collaborating with Marbn on stem cell clinical trials. The first such collaboration follows upon work at Cedars-Sinai in which heart attack patients received infusions of cardiac stem cells. This study, published in February 2012 in The Lancet, showed that patients who underwent the stem cell procedure experienced a significant reduction in the size of the scar left behind by a heart attack. Patients also experienced a sizable increase in healthy heart muscle following the experimental stem cell treatments.
The new study is being directed by Henry and by Raj Makkar, MD, director of Interventional Cardiology and associate director of the Cedars-Sinai Heart Institute. The national trial called ALLSTAR uses heart cells from unrelated donors in an effort to reverse lasting tissue damage after a heart attack.
My goal in joining the Cedars-Sinai Heart Institute is to help make stem cells a regular treatment option for heart disease, Henry said. Right now, many patients with advanced heart disease have limited treatment options. Stem cells are the next frontier.
A native of Mohall, N.D., Henry earned his bachelors degree at the University of North Dakota and his medical degree at the University of California, San Francisco. Following an internship, residency and cardiology research fellowship at University of Colorado Health Sciences Center in Denver, Henry moved to the University of Minnesota and the Minneapolis Heart Institute, where he has focused on interventional cardiology, treatment of patients with acute heart attacks and novel therapy for patients with advanced heart disease who are not candidates for bypass surgery or stenting.
He has authored hundreds of studies published in peer-reviewed medical journals. He currently serves on the Advisory Committee for the AHA Mission: Lifeline Program, the AHA Acute Cardiac Care Committee of the Council on Clinical Cardiology and the Board of the Society of Chest Pain Centers. He has served as national principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and angiogenesis including several ongoing cardiovascular stem cell trials, including RENEW, ALLSTAR and ATHENA. He is also principal investigator for one of seven NIH Clinical Cardiovascular Stem Cell Centers. As a visiting professor, Henry has lectured throughout the world on systems of care for acute myocardial infarction, refractory angina and stem cell therapy for cardiovascular disease. The process to grow cardiac-derived stem cells was developed by Dr. Marbn when he was on the faculty of Johns Hopkins University. Johns Hopkins has filed for a patent on that intellectual property and has licensed it to Capricor, a company in which Cedars-Sinai and Marbn have a financial interest. Capricor is providing funds for the ALLSTAR clinical study at Cedars-Sinai.
View original post here:
Stem cell clinical trials expert to lead Cardiology Division …
Posted: November 23, 2013 at 11:41 am
Cord Blood Registry
Call our Specialists
Connecting clients to the regenerative potential of stem cell medicine
In addition to current, FDA-regulated clinical trials, the same types of stem cells that are found in cord blood and cord tissue are being used in early-stage research. Although researchers can’t say what these studies will yield, newborn stem cells are demonstrating a growing range of potential uses across a variety of therapeutic areas.
Stroke Mesenchymal stem cells found in cord tissue are being evaluated in animal studies for their ability to treat ishemic stroke, a condition that occurs when an artery to the brain is blocked. Animals treated with cord tissue stem cells experienced a decrease in the size of injury, with increased blood flow to the affected area. Treated animals also experienced increased motor control, likely due to the stem cells’ ability to secrete factors that promote blood flow and encourage the brain’s natural healing process.16
Parkinson’s DiseaseEarly laboratory studies suggest that mesenchymal stem cells from cord tissue can help improve motor function in animals afflicted with Parkinson’s disease, a disorder of the nervous system that affects movement. The study indicated that the stem cells reduced some functional effects of the disease, making stem cell treatment a potential therapeutic strategy.17
Alzheimer’s Disease Alzheimer’s disease is an irreversible neurodegenerative disease that is characterized by insoluble protein deposits in the brain called beta amyloids. A study evaluating the effect of human cord blood mesenchymal stem cells on Alzheimer’s disease in mice showed a marked reduction in beta amyloids, as the stem cells actively migrated to the affected parts of the brain. These results have led to human clinical trials.18
Heart Disease Mounting evidence shows that mesenchymal stem cells derived from cord tissue may provide a valuable tool for fighting heart disease. Early laboratory studies demonstrate that, under specific conditions, these stem cells could be induced to become heart muscle cells. Based on these results, researchers propose moving forward with animal studies to better understand their potential as therapy for heart disease in humans.19
Peripheral Artery Occlusive Disease Peripheral artery occlusive disease, a hardening and narrowing of the arteries that supply blood to the arms and legs, can result in decreased blood flow to the limbs, which could result in pain, wounds that don’t heal properly, and a noticeable change in skin color. Animal studies using stem cells from cord blood show promising results in the creation of new blood vessels and restoring blood flow. In animals, limbs injected with cord blood stem cells experienced an increase in the number and density of blood vessels over the limbs that weren’t injected.20
Continue reading here:
Stem Cell Clinical Trials Use Stem Cells Banked With CBR®